AU Patent

AU2018304373B2 — Compositions comprising darunavir, cobicistat, emtricitabine and tenofovir alafenamide for use in the treatment of HIV

Assigned to Janssen Sciences Ireland ULC · Expires 2024-08-01 · 2y expired

What this patent protects

The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.

USPTO Abstract

The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018304373B2
Jurisdiction
AU
Classification
—
Expires
2024-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.